Can a rabbit monoclonal antibody tell a phosphorylated site from the unmodified one?
What this proves about making phospho-specific antibodies
Phospho-specific antibodies are among the hardest reagents to make well. The antibody has to discriminate a single phosphate group — roughly 80 daltons on an otherwise identical peptide — and it has to keep doing so against the whole proteome in a Western blot or an IHC section. Most campaigns that fail do so quietly: the antibody works on the immunizing peptide and falls apart on real samples.
This paper is a structural account of two antibodies that did not fail, and of why they did not. Three points matter commercially:
- The selectivity is real and it was measured, not assumed. Clone A4 binds the phosphorylated peptide at KD 3.34 nM versus 1.12 µM for the non-phosphorylated peptide. Clone C7 binds the phosphorylated peptide at KD 26.9 nM and gave no detectable binding to the non-phosphorylated peptide under the same conditions.
- Two clones from one campaign solved the same problem two different ways. A4 and C7 use different residues and different geometry to grip the phosphate. That is what a selection-based platform buys you: a panel of mechanistically distinct solutions rather than one lucky clone.
- The mechanism is now visible at atomic resolution. Three crystal structures were deposited (PDB 8ZXW, 8JOW, 8ZPU), so the interaction can be inspected rather than inferred.
The measured numbers
| Clone | KD, phosphorylated peptide | KD, non-phosphorylated peptide | Selectivity |
|---|---|---|---|
| A4 | 3.34 nM | 1.12 µM | 335-fold |
| C7 | 26.9 nM | No binding detected | Not quantifiable — the unmodified peptide does not bind |
Antigen: the Akt pSer473 peptide RPHFPQF(pS)YSAS. Rabbits were immunized, a Fab phage library was built from the immune repertoire, and three rounds of panning followed by ELISA screening returned four phospho-specific clones.
How the antibodies actually grip the phosphate
Alanine-scanning with isothermal titration calorimetry identified which contacts carry the binding energy, and the two clones answer differently.
In A4, a single arginine in the heavy chain (H-R95) is the hot spot: mutating it to alanine essentially abolishes binding. The serine and threonine residues nearby that look like plausible phosphate contacts — H-S53, H-S54, H-T56 — turned out not to matter; each alanine mutant bound indistinguishably from wild type. This is a useful caution: the residues that look important in a static picture often are not the ones doing the work.
In C7, the critical arginine sits elsewhere (H-R53), and two serines that were dispensable in A4 do carry real energy here: H-S52 costs 25-fold when removed and H-S54 costs 4-fold. Molecular dynamics — 1 µs per run, three runs, two protonation states, six microseconds of simulation in total — showed C7 holding its bidentate arginine–phosphate hydrogen bonds essentially the whole time.
The practical read: high phospho-selectivity is not one motif that has to be found. It is an outcome that a large, properly selected repertoire can reach by several routes at once.
Why rabbit, and why phage display rather than hybridoma
Rabbits raise antibodies against phosphorylated self-epitopes that mice tolerate, and they routinely reach affinities where mouse monoclonals sit at nanomolar. But rabbit immunization alone is not the differentiator here — the selection step is. Hybridoma and B-cell cloning sample roughly 104–105 cells and cannot apply selective pressure after the fact. Phage display samples orders of magnitude more of the repertoire and lets a negative selection be built into the campaign: in this work, an excess of soluble non-phosphorylated peptide was present during binding, so clones that could not discriminate were removed before screening ever started.
The library and vector used here are Abwiz Bio technology. The paper’s conflict-of-interest statement records it directly: the authors used the patented technology WizAmp (US 9,890,414), invented by S. C. J. O. and T. M., for antibody acquisition.
Have a phospho-site that other platforms could not resolve?
Tell us the sequence and the assay it has to work in. A PhD scientist — not a sales rep — reads it and replies within two business days. No NDA needed to start.
Talk to a scientist →Frequently asked questions
How selective does a phospho-specific antibody need to be?
It depends on the application. For Western blot and IHC, where the unmodified protein is present in large excess, two orders of magnitude of selectivity is a working minimum and more is better. The clones in this paper sit at 335-fold and at no-detectable-binding respectively, which is why both are usable on real samples rather than only on the immunizing peptide.
Can you make a phospho-specific antibody to any site?
No platform can promise that. What determines feasibility is the sequence context around the phosphosite, whether a discriminating peptide can be synthesized and conjugated sensibly, and whether the surrounding residues give the antibody something to hold onto besides the phosphate. Send us the sequence and we will tell you what we think before you commit to a campaign.
Does the antibody detect the phosphorylated site in a full-length protein, not just a peptide?
That is a separate question from affinity and it has to be tested. Our companion study on methylated lysine showed the highest-affinity clone of the panel failing on Western blot while lower-affinity clones worked, because of how the peptide C-terminus was engaged. We screen for the application, not for the peptide number.
Do you deliver sequences and IP for the clones?
Yes. Standard engagements return the antibody sequences to the sponsor, and there are no downstream royalties in standard scope.
How long does a phospho-specific rabbit campaign take?
Immunization through validated recombinant IgG runs about four to six months for a typical target.